Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

100 results about "KINESIN-BINDING PROTEIN" patented technology

Members of the kinesin superfamily vary in shape but the prototypical kinesin-1 is a heterotetramer whose motor subunits (heavy chains or KHCs) form a protein dimer (molecule pair) that binds two light chains (KLCs).

Antisense modulation of kinesin-like 1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
Owner:IONIS PHARMA INC

Kinesin inhibitors

The present invention provides for compounds, compositions, methods and systems for inhibiting cell growth. More specifically, the present invention provides for methods, compounds and compositions which are capable of inhibiting mitosis in metabolically active cells. Compounds, compositions and methods of the present invention inhibit the activity of a protein involved in the assembly and maintenance of the mitotic spindle. One class of proteins which acts on the mitotic spindle is the family of mitotic kinesins, a subset of the kinesin superfamily.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Mitotic kinesin inhibitors

The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic kinesin inhibitors

The present invention relates to azaquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:COLEMAN PAUL +2

Formulation of small RNA/DNA whitening product and preparation method thereof

The invention relates to a small RNA / DNA whitening product series, which mainly consists of a small RNA skin whitening lotion and a small RNA skin beauty cream. The small RNA skin whitening lotion mainly comprises efficient active ingredients for removing skin pigmentation and whitening skin, such as nano single-strand or double-strand oligonucleotides for specially and efficiency restraining genes (Asip, Mclr, Mitf, Dct, Silv, Oca2, Myo5a, Loc51151, Rab27a, Pomc, OA1,F2rl1, Kinesin, Slc24a5, Tyr and Tyrp1) relevant to melanin generation and a transdermal agent for stimulating oligonucleotides to enter skin melanocytes; the small RNA skin beauty cream comprises a plurality of highly active materials for maintaining pure and white skin and small RNA segments to prevent the sunshine from damaging the protective components of the skin and remove free radicals, and anti-aging and anti-inflammatory effective molecules. In addition, the invention further provides a formulation, a method and a procedure for preparing the series of whitening products.
Owner:JIANGSU GENECON BIOLOGICAL TECH

Mitotic kinesin inhibitors

The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Prodrugs of mitotic kinesin inhibitors

The present invention relates to phosphate ester prodrugs of dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Novel Compositions And Methods Of Treatment

Disclosed inter alia is the use of quinazolinone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The quinazolinone derivatives are administered with another chemotherapeutic agent selected from alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signalling inhibitors (e.g., kinase inhibitors). Pharmaceutical compositions comprising one or both types of active agents are also disclosed.
Owner:CYTOKINETICS INC

Mitotic kinesin inhibitors

The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:FRALEY MARK +1

Mitotic Kinesin Inhibitors

The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic kinesin inhibitors

The present invention relates to azolopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Phenothiazine kinesin inhibitors

InactiveUS20060014736A1Determine effectBiocideOrganic chemistryMedicinePercent Diameter Stenosis
Phenothiazine derivatives of formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
Owner:CYTOKINETICS INC

Mitotic kinesin inhibitors

The present invention relates to thienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic kinesin inhibitors

The present invention relates to azolopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic Kinesin Inhibitors

The present invention relates to tricyclic pyrazoles according to Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic kinesin inhibitors

The present invention relates to dihydropyrimidone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:COLEMAN PAUL +2

Mitotic Kinesin Inhibitors

The present invention relates to fluorinated dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Mitotic kinesin inhibitors

The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP

Methods for screening and therapeutic applications of kinesin modulators

The present invention relates to protein modulators, especially modulators of kinesin bioactivities. The present invention provides methods for screening protein modulators, e.g., kinesin modulators that bind to a region of a kinesin and / or that modulate kinesin bioactivities. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal cellular proliferation activities.
Owner:CYTOKINETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products